LMNL - Liminal BioSciences Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
14.40
-1.91 (-11.71%)
As of 11:18AM EDT. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close16.31
Open15.50
Bid14.28 x 900
Ask14.52 x 800
Day's Range14.04 - 15.73
52 Week Range5.25 - 31.45
Volume40,918
Avg. Volume118,916
Market Cap309.813M
Beta (5Y Monthly)1.58
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Liminal BioSciences to Voluntarily Delist from the Toronto Stock Exchange
      CNW Group

      Liminal BioSciences to Voluntarily Delist from the Toronto Stock Exchange

      LAVAL, QC and CAMBRIDGE, England, July 22, 2020 /CNW Telbec/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announces that it has applied for a voluntarily delisting of its common shares ("Common Shares") from the Toronto Stock Exchange ("TSX") in Canada. Subject to such application being accepted by the TSX, it is expected that the Common Shares will be delisted from the TSX effective as of the close of trading on August 5, 2020.

    • Liminal BioSciences Broadens R&D Pipeline With Novel Preclinical Program For Eosinophilic-Driven Diseases
      PR Newswire

      Liminal BioSciences Broadens R&D Pipeline With Novel Preclinical Program For Eosinophilic-Driven Diseases

      Liminal BioSciences Inc. (Nasdaq: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced today that it has acquired all of the issued and outstanding shares in the capital of Fairhaven Pharmaceuticals Inc. ("Fairhaven"), thus acquiring a preclinical research program of small molecule antagonists. Investigational therapies developed in this program target a key chemoattractant and activator of eosinophils, which play a key role in Type 2 inflammation-driven diseases through tissue repair and resolution of inflammation ("Fairhaven R&D; Program").

    • Liminal BioSciences Joins CoVIg Plasma Alliance to Contribute to Development of Potential New COVID-19 Therapy
      CNW Group

      Liminal BioSciences Joins CoVIg Plasma Alliance to Contribute to Development of Potential New COVID-19 Therapy

      "We are proud to be joining plasma companies Takeda, CSL Behring, ADMA Biologics, Biopharma Plasma, Biotest, BPL, GC Pharma, LFB, Octapharma, Sanquin, and other  contributors and supporters of the CoVIg-19 Plasma Alliance in a unique  partnership of the world's leading plasma-derived therapeutic companies to collaborate and coordinate efforts during the COVID-19 pandemic," stated Kenneth Galbraith , Chief Executive Officer of Liminal BioSciences. Individuals interested in donating plasma can visit https://plasma.prometic.com to find the nearest Prometic Plasma Resources plasma collection center to their location.

    • Liminal BioSciences Commences Collection of Convalescent Plasma from COVID-19 Recovered Donors
      PR Newswire

      Liminal BioSciences Commences Collection of Convalescent Plasma from COVID-19 Recovered Donors

      Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, today announced that Prometic Plasma Resources, a subsidiary of Liminal BioSciences, has commenced the collection of convalescent plasma from donors who have recovered from COVID-19.

    • Liminal BioSciences Provides Guidance Update on Certain Expected Key Milestones For 2020
      CNW Group

      Liminal BioSciences Provides Guidance Update on Certain Expected Key Milestones For 2020

      Liminal BioSciences Provides Guidance Update on Certain Expected Key Milestones For 2020

    • Liminal BioSciences to Present at Raymond James Human Health Innovation Conference
      CNW Group

      Liminal BioSciences to Present at Raymond James Human Health Innovation Conference

      Liminal BioSciences to Present at Raymond James Human Health Innovation Conference

    • Liminal Announces Voting Results of Its 2020 Annual And Special General Meeting Of Shareholders (AGM)
      CNW Group

      Liminal Announces Voting Results of Its 2020 Annual And Special General Meeting Of Shareholders (AGM)

      LAVAL, QC and CAMBRIDGE, United Kingdom , June 9, 2020 /CNW/ - Liminal BioSciences Inc. (Nasdaq & TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company today announced the voting results from its Annual General and Special Meeting of Shareholders ("AGM") held virtually on June 8, 2020 . A total of 20,352,943 common shares were voted, representing 86.90% of the votes attached to the issued and outstanding common shares of Liminal BioSciences. The seven (7) nominees set forth in the Circular were elected as directors of the Company to hold office until the next annual meeting of shareholders or until their successors are elected or appointed.

    • Liminal BioSciences to present at Jefferies Virtual Healthcare Conference
      CNW Group

      Liminal BioSciences to present at Jefferies Virtual Healthcare Conference

      Liminal BioSciences to present at Jefferies Virtual Healthcare Conference

    • Investors Who Bought Liminal BioSciences (TSE:LMNL) Shares Five Years Ago Are Now Down 100%
      Simply Wall St.

      Investors Who Bought Liminal BioSciences (TSE:LMNL) Shares Five Years Ago Are Now Down 100%

      Liminal BioSciences Inc. (TSE:LMNL) shareholders should be happy to see the share price up 12% in the last week. But...

    • Liminal Biosciences Reports Q1 2020 Results
      CNW Group

      Liminal Biosciences Reports Q1 2020 Results

      Liminal BioSciences will host a conference call at 8:30am (EDT) on Thursday May 14, 2020. "We have taken substantial steps to safeguard our employees and wider community from the COVID-19 pandemic by implementing business continuity plans," said Kenneth Galbraith , Liminal BioSciences' Chief Executive Officer.

    • ACCESSWIRE

      Liminal BioSciences, Inc. to Host Earnings Call

      NEW YORK, NY / ACCESSWIRE / March 23, 2020 / Liminal BioSciences, Inc. (NASDAQ:LMNL) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 23, 2020 at ...

    • Liminal BioSciences comments on Coronavirus (COVID-19)
      PR Newswire

      Liminal BioSciences comments on Coronavirus (COVID-19)

      Liminal BioSciences Inc. (Nasdaq: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel treatments for patients suffering from diseases related to fibrosis, including respiratory, liver and kidney diseases that have high unmet medical need, commented today on the impact of the current COVID-19 pandemic on its operations.

    • Liminal Biosciences Reports Fourth Quarter and 2019 Year End Results
      PR Newswire

      Liminal Biosciences Reports Fourth Quarter and 2019 Year End Results

      Liminal BioSciences Inc. (Nasdaq: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel treatments for patients suffering from diseases related to fibrosis, including respiratory, liver and kidney diseases that have high unmet medical need, today reported its financial results for the fourth quarter and year-ended December 31, 2019.

    • Liminal BioSciences to report its fourth quarter and year-end 2019 financial results and hold conference call/webcast
      PR Newswire

      Liminal BioSciences to report its fourth quarter and year-end 2019 financial results and hold conference call/webcast

      Liminal BioSciences Inc. (Nasdaq: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel treatments for patients suffering from diseases related to fibrosis, including respiratory, liver and kidney diseases that have high unmet medical need, announced today it will report its financial results for the fourth quarter and financial year ended December 31, 2019 on Friday March 20, 2020 after market close.

    • Liminal BioSciences Announces Scientific Presentations at Upcoming Keystone Symposia
      PR Newswire

      Liminal BioSciences Announces Scientific Presentations at Upcoming Keystone Symposia

      Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company" ), a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, today announced the Company and its collaborators will present scientific findings at two upcoming Keystone Symposia : (i) Fibrosis and Tissue Repair: From Molecules and Mechanics to Therapeutic Approaches being held on February 19-23, 2020 in Victoria, Canada; and (ii) Obesity and NAFLD: Mechanisms and Therapeutics being held on February 23-27, 2020 in Banff, Canada.

    • Liminal BioSciences announces upcoming investor presentation at BIO CEO & Investor Conference
      CNW Group

      Liminal BioSciences announces upcoming investor presentation at BIO CEO & Investor Conference

      Liminal BioSciences is an innovative biopharmaceutical company with a broad pipeline of small molecule therapeutics under development to address unmet needs in patients with liver, respiratory and kidney disease, with a focus on rare and orphan diseases. Liminal BioSciences' research involves the study of several G-protein-coupled-receptors, known as free fatty acid receptors (FFAR's).

    • Liminal BioSciences Outlines Corporate Priorities for 2020
      PR Newswire

      Liminal BioSciences Outlines Corporate Priorities for 2020

      Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ( "Liminal BioSciences" or the "Company" ), a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, today provided a corporate update and outlined its key corporate and R&D; priorities for 2020.

    • Liminal BioSciences Comments on Unusual Market Activity
      CNW Group

      Liminal BioSciences Comments on Unusual Market Activity

      Liminal BioSciences Comments on Unusual Market Activity

    • AMF Concludes its Review of the Refinancing Transactions Completed by Liminal BioSciences in April 2019
      CNW Group

      AMF Concludes its Review of the Refinancing Transactions Completed by Liminal BioSciences in April 2019

      LAVAL, QC , ROCKVILLE, MD and CAMBRIDGE, United Kingdom , Nov. 28, 2019 /CNW Telbec/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ( "Liminal BioSciences" or the "Company" ), a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, acknowledges the press release issued today by the Autorité des Marchés Financiers ("AMF") in which the AMF announced that after a thorough investigation, the AMF has determined that no violation or breach of securities regulation occurred in connection with the refinancing transactions completed by the Company in April 2019 . The AMF is the regulatory and oversight body for Québec's financial sector.

    • Liminal BioSciences to Present at Piper Jaffray Healthcare Conference
      PR Newswire

      Liminal BioSciences to Present at Piper Jaffray Healthcare Conference

      Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, announced today, today announced that members of the management team will provide a business overview and update at the Piper Jaffray 31st Annual Healthcare Conference at 08:10 ET on Wednesday, December 4, 2019 in New York, USA.

    • CNW Group

      Liminal BioSciences announces closing of divestiture of bioseparations division to KKR

      LAVAL, QC , ROCKVILLE, MD and CAMBRIDGE, UK , Nov. 25, 2019 /CNW Telbec/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, announced today it has closed on the previously announced divestment of its Isle of Man -based bioseparations business operated through its subsidiary Prometic Bioseparations Ltd. ("PBL") to KKR & Co., a leading global investment firm ("KKR"). "We are very pleased to close on the sale of our bioseparations business to KKR" said Kenneth Galbraith , the CEO of Liminal BioSciences.

    • Liminal Biosciences announces effectiveness of Registration Statement on Form F-10 and filing of Prospectus Supplement
      CNW Group

      Liminal Biosciences announces effectiveness of Registration Statement on Form F-10 and filing of Prospectus Supplement

      LAVAL, QC , ROCKVILLE, MD and CAMBRIDGE, United Kingdom , Nov. 18, 2019 /CNW Telbec/ - Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biotechnology company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, announced today that its registration statement on Form F-10 (the "Registration Statement"), which was filed with the United States Securities and Exchange Commission (the "SEC") on November 12, 2019 under the Canada-U.S. multijurisdictional disclosure system, was declared effective on November 15, 2019 . The registration statement contains the previously filed final short form base shelf prospectus dated March 14, 2018 (the "Shelf Prospectus"), which was prepared in accordance with the shelf prospectus regulations under Canadian securities legislation and has now been filed under the Canada-U.S. multijurisdictional disclosure system as part of the Registration Statement.